These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 28521697)

  • 1. An Accelerated Release Method of Risperidone Loaded PLGA Microspheres with Good IVIVC.
    Hu X; Zhang J; Tang X; Li M; Ma S; Liu C; Gao Y; Zhang Y; Liu Y; Yu F; Yang Y; Guo J; Li Z; Mei X
    Curr Drug Deliv; 2018; 15(1):87-96. PubMed ID: 28521697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro-in vivo correlation of parenteral risperidone polymeric microspheres.
    Shen J; Choi S; Qu W; Wang Y; Burgess DJ
    J Control Release; 2015 Nov; 218():2-12. PubMed ID: 26423236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of andrographolide loaded PLGA microspheres: optimization, characterization and in vitro-in vivo correlation.
    Jiang Y; Wang F; Xu H; Liu H; Meng Q; Liu W
    Int J Pharm; 2014 Nov; 475(1-2):475-84. PubMed ID: 25219858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained release of risperidone from biodegradable microspheres prepared by in-situ suspension-evaporation process.
    An T; Choi J; Kim A; Lee JH; Nam Y; Park J; Sun Bk; Suh H; Kim CJ; Hwang SJ
    Int J Pharm; 2016 Apr; 503(1-2):8-15. PubMed ID: 26899975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microsphere delivery of Risperidone as an alternative to combination therapy.
    D'Souza S; Faraj J; DeLuca P
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):631-9. PubMed ID: 23892159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel accelerated in vitro release method to evaluate the release of thymopentin from PLGA microspheres.
    Xie X; Li Z; Zhang L; Chi Q; Yang Y; Zhang H; Yang Y; Mei X
    Pharm Dev Technol; 2015; 20(5):633-40. PubMed ID: 24597702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro-in vivo correlation of PLGA microspheres: Effect of polymer source variation and temperature.
    Wan B; Bao Q; Burgess DJ
    J Control Release; 2022 Jul; 347():347-355. PubMed ID: 35569590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterizing release mechanisms of leuprolide acetate-loaded PLGA microspheres for IVIVC development I: In vitro evaluation.
    Hirota K; Doty AC; Ackermann R; Zhou J; Olsen KF; Feng MR; Wang Y; Choi S; Qu W; Schwendeman AS; Schwendeman SP
    J Control Release; 2016 Dec; 244(Pt B):302-313. PubMed ID: 27565212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A reproducible accelerated in vitro release testing method for PLGA microspheres.
    Shen J; Lee K; Choi S; Qu W; Wang Y; Burgess DJ
    Int J Pharm; 2016 Feb; 498(1-2):274-82. PubMed ID: 26705156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly(D,L-lactide-co-glycolide) microsphere.
    Su Z; Sun F; Shi Y; Jiang C; Meng Q; Teng L; Li Y
    Chem Pharm Bull (Tokyo); 2009 Nov; 57(11):1251-6. PubMed ID: 19881277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preparation and evaluation of risperidone-loaded microsphere/sucrose acetate isobutyrate in situ forming complex depot with double diffusion barriers].
    Lin X; Tang X; Xu YH; Zhang Y; Zhang Y; He HB
    Yao Xue Xue Bao; 2015 Jun; 50(6):775-82. PubMed ID: 26521452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond Q1/Q2: The Impact of Manufacturing Conditions and Test Methods on Drug Release From PLGA-Based Microparticle Depot Formulations.
    Garner J; Skidmore S; Park H; Park K; Choi S; Wang Y
    J Pharm Sci; 2018 Jan; 107(1):353-361. PubMed ID: 29107048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of in vitro-in vivo release of Risperdal(®) Consta(®) microspheres.
    Rawat A; Bhardwaj U; Burgess DJ
    Int J Pharm; 2012 Sep; 434(1-2):115-21. PubMed ID: 22659126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerated in vitro release testing method for naltrexone loaded PLGA microspheres.
    Andhariya JV; Choi S; Wang Y; Zou Y; Burgess DJ; Shen J
    Int J Pharm; 2017 Mar; 520(1-2):79-85. PubMed ID: 28153651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IVIVC of parenteral PLGA microspheres.
    Park K
    J Control Release; 2015 Nov; 218():116. PubMed ID: 26526216
    [No Abstract]   [Full Text] [Related]  

  • 16. Development of in vitro-in vivo correlation of parenteral naltrexone loaded polymeric microspheres.
    Andhariya JV; Shen J; Choi S; Wang Y; Zou Y; Burgess DJ
    J Control Release; 2017 Jun; 255():27-35. PubMed ID: 28385676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of bases with different solubility on the release behavior of risperidone loaded PLGA microspheres.
    Hu Z; Liu Y; Yuan W; Wu F; Su J; Jin T
    Colloids Surf B Biointerfaces; 2011 Aug; 86(1):206-11. PubMed ID: 21524893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3-month parenteral PLGA microsphere formulations of risperidone: Fabrication, characterization and neuropharmacological assessments.
    Chaurasia S; Mounika K; Bakshi V; Prasad V
    Mater Sci Eng C Mater Biol Appl; 2017 Jun; 75():1496-1505. PubMed ID: 28415443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation.
    Su ZX; Shi YN; Teng LS; Li X; Wang LX; Meng QF; Teng LR; Li YX
    Pharm Dev Technol; 2011 Aug; 16(4):377-84. PubMed ID: 20370594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro-In Vivo Relationship of Amorphous Insoluble API (Progesterone) in PLGA Microspheres.
    Pu C; Wang Q; Zhang H; Gou J; Guo Y; Tan X; Xie B; Yin N; He H; Zhang Y; Wang Y; Yin T; Tang X
    Pharm Res; 2017 Dec; 34(12):2787-2797. PubMed ID: 28948463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.